A critical limitation to deployment and utilization of Artificial Intelligence (AI) algorithms in radiology practice is the actual integration of algorithms directly into the clinical Picture Archiving and Communications Systems (PACS). Here, we sought to integrate an AI-based pipeline for prostate organ and intraprostatic lesion segmentation within a clinical PACS environment to enable point-of-care utilization under a prospective clinical trial scenario. A previously trained, publicly available AI model for segmentation of intra-prostatic findings on multiparametric Magnetic Resonance Imaging (mpMRI) was converted into a containerized environment compatible with MONAI Deploy Express. An inference server and dedicated clinical PACS workflow were established within our institution for evaluation of real-time use of the AI algorithm. PACS-based deployment was prospectively evaluated in two phases: first, a consecutive cohort of patients undergoing diagnostic imaging at our institution and second, a consecutive cohort of patients undergoing biopsy based on mpMRI findings. The AI pipeline was executed from within the PACS environment by the radiologist. AI findings were imported into clinical biopsy planning software for target definition. Metrics analyzing deployment success, timing, and detection performance were recorded and summarized. In phase one, clinical PACS deployment was successfully executed in 57/58 cases and were obtained within one minute of activation (median 33 s [range 21-50 s]). Comparison with expert radiologist annotation demonstrated stable model performance compared to independent validation studies. In phase 2, 40/40 cases were successfully executed via PACS deployment and results were imported for biopsy targeting. Cancer detection rates for prostate cancer were 82.1% for ROI targets detected by both AI and radiologist, 47.8% in targets proposed by AI and accepted by radiologist, and 33.3% in targets identified by the radiologist alone. Integration of novel AI algorithms requiring multi-parametric input into clinical PACS environment is feasible and model outputs can be used for downstream clinical tasks.

Although there are notable structural abnormalities in the brain associated with psychotic diseases, it is still unclear how these abnormalities relate to clinical presentation. However, the fractal dimension (FD), which offers details on the complexity and irregularity of brain microstructures, may be a promising feature, as demonstrated by neuropsychiatric disorders such as Parkinson's and Alzheimer's. It may offer a possible biomarker for the detection and prognosis of psychosis when paired with machine learning. The purpose of this study is to investigate FD as a structural magnetic resonance imaging (sMRI) feature from individuals with a high clinical risk of psychosis who did not transit to psychosis (CHR_NT), clinical high risk who transit to psychosis (CHR_T), patients with first-episode psychosis (FEP) and healthy controls (HC). Using a machine learning approach that ultimately classifies sMRI images, the goals are (a) to evaluate FD as a potential biomarker and (b) to investigate its ability to predict a subsequent transition to psychosis from the high-risk clinical condition. We obtained sMRI images from 194 subjects, including 44 HCs, 77 FEPs, 16 CHR_Ts, and 57 CHR_NTs. We extracted the FD features and analyzed them using machine learning methods under five classification schemas (a) FEP vs. HC, (b) FEP vs. CHR_NT, (c) FEP vs. CHR_T, (d) CHR_NT vs. CHR_T, (d) CHR_NT vs. HC and (e) CHR_T vs. HC. In addition, the CHR_T group was used as external validation in (a), (b) and (d) comparisons to examine whether the progression of the disorder followed the FEP or CHR_NT patterns. The proposed algorithm resulted in a balanced accuracy greater than 0.77. This study has shown that FD can function as a predictive neuroimaging marker, providing fresh information on the microstructural alterations triggered throughout the course of psychosis. The effectiveness of FD in the detection of psychosis and transition to psychosis should be established by further research using larger datasets.

MRI sequence classification becomes challenging in multicenter studies due to variability in imaging protocols, leading to unreliable metadata and requiring labor-intensive manual annotation. While numerous automated MRI sequence identification models are available, they frequently encounter the issue of domain shift, which detrimentally impacts their accuracy. This study addresses domain shift, particularly from adult to pediatric MRI data, by evaluating the effectiveness of pre-trained models under these conditions. This retrospective and multicentric study explored the efficiency of a pre-trained convolutional (ResNet) and CNN-Transformer hybrid model (MedViT) to handle domain shift. The study involved training ResNet-18 and MedVit models on an adult MRI dataset and testing them on a pediatric dataset, with expert domain knowledge adjustments applied to account for differences in sequence types. The MedViT model demonstrated superior performance compared to ResNet-18 and benchmark models, achieving an accuracy of 0.893 (95% CI 0.880-0.904). Expert domain knowledge adjustments further improved the MedViT model's accuracy to 0.905 (95% CI 0.893-0.916), showcasing its robustness in handling domain shift. Advanced neural network architectures like MedViT and expert domain knowledge on the target dataset significantly enhance the performance of MRI sequence classification models under domain shift conditions. By combining the strengths of CNNs and transformers, hybrid architectures offer enhanced robustness for reliable automated MRI sequence classification in diverse research and clinical settings. Question Domain shift between adult and pediatric MRI data limits deep learning model accuracy, requiring solutions for reliable sequence classification across diverse patient populations. Findings The MedViT model outperformed ResNet-18 in pediatric imaging; expert domain knowledge adjustment further improved accuracy, demonstrating robustness across diverse datasets. Clinical relevance This study enhances MRI sequence classification by leveraging advanced neural networks and expert domain knowledge to mitigate domain shift, boosting diagnostic precision and efficiency across diverse patient populations in multicenter environments.

Functional magnetic resonance imaging (fMRI) has demonstrated significant potential in the early diagnosis and study of pathological mechanisms of Alzheimer's disease (AD). To fit subtle cross-spatiotemporal interactions and learn pathological features from fMRI, we proposed a fine-grained spatiotemporal graph neural network with self-supervised learning (SSL) for diagnosis and biomarker extraction of early AD. First, considering the spatiotemporal interaction of the brain, we designed two masks that leverage the spatial correlation and temporal repeatability of fMRI. Afterwards, temporal gated inception convolution and graph scalable inception convolution were proposed for the spatiotemporal autoencoder to enhance subtle cross-spatiotemporal variation and learn noise-suppressed signals. Furthermore, a spatiotemporal scalable cosine error with high selectivity for signal reconstruction was designed in SSL to guide the autoencoder to fit the fine-grained pathological features in an unsupervised manner. A total of 5,687 samples from four cross-population cohorts were involved. The accuracy of our model was 5.1% higher than the state-of-the-art models, which included four AD diagnostic models, four SSL strategies, and three multivariate time series models. The neuroimaging biomarkers were precisely localized to the abnormal brain regions, and correlated significantly with the cognitive scale and biomarkers (P$< $0.001). Moreover, the AD progression was reflected through the mask reconstruction error of our SSL strategy. The results demonstrate that our model can effectively capture spatiotemporal and pathological features, and providing a novel and relevant framework for the early diagnosis of AD based on fMRI.

This study aimed to predict and classify MRI PI-RADs scores using different machine learning algorithms and to detect the concordance of PI-RADs scoring with the outcome target of prostate biopsy. Machine learning (ML) algorithms were used to develop best-fitting models for the prediction and classification of MRI PI-RAD. The Random Forest and Extra Trees models achieved the best performance compared to the other methods. The accuracy of both models was 91.95%. The AUC was 0.9329 for the Random Forest model and 0.9404 for the Extra Trees model. PSA level, PSA density, and diameter of the largest lesion were the most important features for the importance of outcome classification. ML prediction enhanced the PI-RAD classification, where clinically significant prostate cancer (csPCa) cases increased from 0% to 1.9% in the low-risk PI-RAD class, this showed that the model identified some previously missed cases. Predictive machine learning models showed an excellent ability to predict MRI Pi-RAD scores and discriminate between low- and high-risk scores. However, caution should be exercised, as a high percentage of negative biopsy cases were assigned Pi-RAD 4 and Pi-RAD 5 scores. ML integration may enhance PI-RAD's utility by reducing unnecessary biopsies in low-risk patients (via better csPCa detection) and refining the high-risk categorization. Combining such PI-RAD scores with significant parameters, such as PSA density, lesion diameter, number of lesions, and age, in decision curve analysis and utility paradigms would assist physicians' clinical decisions.

Brain tumors pose a severe health risk, often leading to fatal outcomes if not detected early. While most studies focus on improving classification accuracy, this research emphasizes prediction certainty, quantified through loss values. Traditional metrics like accuracy and precision do not capture confidence in predictions, which is critical for medical applications. This study establishes a correlation between lower loss values and higher prediction certainty, ensuring more reliable tumor classification. We evaluate CNN, ResNet50, XceptionNet, and a Proposed Model (VGG19 with customized classification layers) using accuracy, precision, recall, and loss. Results show that while accuracy remains comparable across models, the Proposed Model achieves the best performance (96.95 % accuracy, 0.087 loss), outperforming others in both precision and recall. These findings demonstrate that certainty-aware AI models are essential for reliable clinical decision-making. This study highlights the potential of AI to bridge the shortage of medical professionals by integrating reliable diagnostic tools in healthcare. AI-powered systems can enhance early detection and improve patient outcomes, reinforcing the need for certainty-driven AI adoption in medical imaging.

Current study aimed to investigate radiomics features derived from two-center diffusion-MRI to differentiate benign and hepatocellular carcinoma (HCC) liver nodules. A total of 328 patients with 517 LI-RADS 2-5 nodules were included. MR images were retrospectively collected from 3 T and 1.5 T MRI vendors. Lesions were categorized into 242 benign and 275 HCC based on follow-up imaging for LR-2,3 and pathology results for LR4,5 nodules, and randomly divided into training (80%) and test (20%) sets. Preprocessing included resampling and normalization. Radiomics features were extracted from lesion volume-of-interest (VOI) on diffusion Images. Scanner variability was corrected using ComBat harmonization method followed by High-correlation filter, PCA filter, and LASSO to select important features. Best classifier model was selected by 10-fold cross-validation, and accuracy was assessed on the test dataset. 1,434 features were extracted, and subsequent classifiers were constructed based on the 16 most important selected features. Notably, support-vector machine (SVM) demonstrated better performance in the test dataset in distinguishing between benign and HCC nodules, achieving an accuracy of 0.92, sensitivity of 0.94, and specificity of 0.86. Utilizing diffusion-MRI radiomics, our study highlights the performance of SVM, trained on lesions' diffusivity characteristics, in distinguishing benign and HCC nodules, ensuring clinical potential. It is suggested that further evaluations be conducted on multi-center datasets to address harmonization challenges. Integration of diffusion radiomics, for monitoring water restriction patterns as tumor histopathological index, with machine learning models demonstrates potential for achieving a reliable noninvasive method to improve the current diagnosis criteria.

This paper presents a deep learning model for the automated segmentation of cerebral cavernous malformations (CCMs). The model was trained using treatment planning data from 199 Gamma Knife (GK) exams, comprising 171 cases with a single CCM and 28 cases with multiple CCMs. The training data included initial MRI images with target CCM regions manually annotated by neurosurgeons. For the extraction of data related to the brain parenchyma, we employed a mask region-based convolutional neural network (Mask R-CNN). Subsequently, this data was processed using a 3D convolutional neural network known as DeepMedic. The efficacy of the brain parenchyma extraction model was demonstrated via five-fold cross-validation, resulting in an average Dice similarity coefficient of 0.956 ± 0.002. The segmentation models used for CCMs achieved average Dice similarity coefficients of 0.741 ± 0.028 based solely on T2W images. The Dice similarity coefficients for the segmentation of CCMs types were as follows: Zabramski Classification type I (0.743), type II (0.742), and type III (0.740). We also developed a user-friendly graphical user interface to facilitate the use of these models in clinical analysis. This paper presents a deep learning model for the automated segmentation of CCMs, demonstrating sufficient performance across various Zabramski classifications. not applicable.

'Brain age' is a biological clock typically used to describe brain health with one number, but its relationship with established gradients of cortical organization remains unclear. We address this gap by leveraging a data-driven, region-specific brain age approach in 335 neurologically intact adults, using a convolutional neural network (volBrain) to estimate regional brain ages directly from structural MRI without a predefined set of morphometric properties. Six distinct gradients of brain aging are replicated in two independent cohorts. Spatial patterns of accelerated brain aging in older adults quantitatively align with the archetypal sensorimotor-to-association axis of cortical organization. Other brain aging gradients reflect neurobiological hierarchies such as gene expression and externopyramidization. Participant-level correspondences to brain age gradients are associated with cognitive and sensorimotor performance and explained behavioral variance more effectively than global brain age. These results suggest that regional brain age patterns reflect fundamental principles of cortical organization and behavior.

Accurate prediction of major adverse cardiovascular events recurrence risk in acute myocardial infarction patients based on postoperative cardiac MRI and associated clinical notes is crucial for precision treatment and personalized intervention. Existing methods primarily focus on risk stratification capability while overlooking the need for intermediate robust reasoning and model interpretability in clinical practice. Moreover, end-to-end risk prediction using LLM/VLM faces significant challenges due to data limitations and modeling complexity. To bridge this gap, we propose CardioCoT, a novel two-stage hierarchical reasoning-enhanced survival analysis framework designed to enhance both model interpretability and predictive performance. In the first stage, we employ an evidence-augmented self-refinement mechanism to guide LLM/VLMs in generating robust hierarchical reasoning trajectories based on associated radiological findings. In the second stage, we integrate the reasoning trajectories with imaging data for risk model training and prediction. CardioCoT demonstrates superior performance in MACE recurrence risk prediction while providing interpretable reasoning processes, offering valuable insights for clinical decision-making.